Experts: Molecular Tests Could Improve Antibiotic Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
Greater acceptance of molecular tests that can identify rare and drug-resistant bacterial strains through their genetic material could transform antibiotics clinical trial design and lower the cost of developing new drugs, scientists said at a workshop on antibiotic drug resistance last week